Target intelligence / Profile preview

Intraflagellar transport protein 80 homolog (IFT80)

Target
IFT80
Molecular classification
Structural protein, Intraflagellar transport complex component, WD repeat protein (contains WD40 domains), Other
01

Overview

Intraflagellar transport protein 80 homolog (IFT80) is a key structural component of the intraflagellar transport-B (IFT-B) complex, which is essential for the assembly and maintenance of cilia and flagella, critical organelles for cellular motility, sensory perception, and developmental signaling[1][2][3][4][5]. IFT80 comprises multiple WD40 repeat domains that form β-propeller structures, enabling it to mediate interactions within the IFT-B complex—primarily via IFT38—and to promote higher-order complex formation through homo-dimerization[1][3][5]. Changes in this protein, especially loss-of-function mutations, disrupt normal ciliogenesis and are directly associated with human genetic disorders, most notably Jeune asphyxiating thoracic dystrophy and short rib polydactyly type III, which manifest with skeletal abnormalities and multisystem malformations[5]. IFT80 also plays a role in osteogenesis, partly through modulation of the Hedgehog-Gli signaling pathway[5]. No pharmacological agents are currently known to act directly on IFT80, and given its crucial role in a core cellular process, it is not considered a conventional drug target.

Other names
Intraflagellar transport protein 80 homologIFT80WD repeat-containing protein 56WDR56KIAA1374FAP167CFAP167ATD2SRTD2
02

Mechanism of action

Not applicable (no approved or investigational drugs are known to act directly on IFT80).

03

Biological functions

Ciliogenesis (formation of cilia)Ciliary cargo transport (within the IFT-B complex)Osteogenesis (bone formation, through regulation of Hedgehog/Gli signaling)Cellular organization
04

Disease associations

CiliopathiesSkeletal dysplasias (Jeune asphyxiating thoracic dystrophy, short rib polydactyly type III)Developmental disorders (including abnormal bones, organ malformations)Other (possible respiratory insufficiency due to skeletal defects)
05

Safety considerations

Therapeutic targeting of IFT80 would potentially disrupt cilia formation and function in most cell types, leading to multi-organ dysfunction, so targeting is not considered safe or feasible
06

Biomarkers

IFT80 mutations can serve as genetic biomarkers for ciliopathies and specific skeletal dysplasias such as Jeune asphyxiating thoracic dystrophy and short rib polydactyly type III

Beyond the preview

Go deeper on Intraflagellar transport protein 80 homolog (IFT80).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intraflagellar transport protein 80 homolog (IFT80).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call